REYOBIQ™ Clinical Trial for Recurrent Glioma Featured in Oncolytics Today
We’re proud to share that Plus Therapeutics’ innovative work on REYOBIQ™ (rhenium-186 Re obisbemeda) has been featured as the cover story in the latest issue of Oncolytics Today, published by NCODA.
In the article titled “A New Way to Treat Brain Cancer?”, Andrew Brenner, M.D., Ph.D. of UT Health San Antonio, highlights findings from our Phase 1 clinical trial investigating REYOBIQ™ for the treatment of recurrent glioblastoma (GBM).
The publication focuses on the safety, tolerability, and preliminary efficacy of 186Re delivered via convection-enhanced delivery (CED), a novel method designed to precisely deliver radiation therapy directly into the tumor, minimizing damage to healthy brain tissue.
📖 Read the full feature in Oncolytics Today: https://bit.ly/3S40Mwh
Now Enrolling: ReSPECT-GBM Phase 2 Clinical Trial
We are currently recruiting glioblastoma (GBM) patients for the ongoing ReSPECT-GBM Phase 2 trial. If you or someone you know may be eligible, visit our clinical trial website or reach out to our team:
https://bit.ly/4lIP5Zt
📩 Email: respect@plustherapeutics.com
#REYOBIQ #Rhenium186Obisbemeda #Glioblastoma #BrainCancer #RecurrentGlioma #CED #ConvectionEnhancedDelivery #ClinicalTrials #RESPECTGBM #Phase1 #OncologyResearch #CancerTreatment #OncolyticsToday #NCODA #UTHealthSA #PlusTherapeutics
Recent Comments